YM866, a novel modified tissue-type plasminogen activator, affects left ventricular function and myocardial infarct development in dogs with coronary artery thrombi

Japanese Journal of Pharmacology

Volumn 77, Issue 3, 1998, Pages 177-183

  Suzuki, Masanori ^a   Funatsu, Toshiyuki ^a   Tanaka, Hideyuki ^a   Usuda, Shinji ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Coronary artery thrombosis; Left ventricular ejection fraction (LVEF); Modified tissue type plasminogen activator; Myocardial infarction; Thrombolysis

Indexed keywords

ALTEPLASE; PAMITEPLASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DISEASE SEVERITY; DOG; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FIBRINOLYTIC THERAPY; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE REPERFUSION; HEART RATE; INTRAVENOUS DRUG ADMINISTRATION; MEAN ARTERIAL PRESSURE; NONHUMAN;

EID: 0031689881     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.77.177     Document Type: Article

References (30)

1. Collen D, Lijnen HR, Todd PA and Goa KL: Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent. Drugs 38, 346-388 (1989)
2. Sheehan FH, Doerret R, Schmidt WG, Bolson EL, Uebis R, Von Essen ER and Dodge HT: Early recovery of left ventricular function after thrombolytic therapy for acute myocardial infarction: An important determinant of survival. J Am Coll Cardiol 12, 289-300 (1988)
3. Topol EJ, Bates ER, Walton JA Jr, Baumann G, Wolfe S, Maino J, Bayer L, Gorman L, Kline EM and O'Neill WW: Community hospital administration of intravenous tissue plasminogen activator in acute myocardial infarction: improved timing, thrombolytic efficacy and ventricular function. J Am Coll Cardiol 10, 1173-1177 (1987)
4. Sheehan FH, Braunwald E, Canner P, Dodge HT, Gore J, Van Natta P, Passamani ER, Williams DO and Zaret B: The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the thrombolysis in myocardial infarction (TIMI phase I) trial. Circulation 75, 817-829 (1987)
5. Gold HK, Leinbach RC, Garabedian HD, Yasuda T, Johns JA, Grossbard EB, Palacios I and Collen D: Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator: prevention by a maintenance infusion. Circulation 73, 347-352 (1986)
6. Kawauchi Y, Morinaga T, Yokota M, Kinoshita A, Kawamura K, Suzuki Y, Takayama M, Furuichi K and Gushima H: Gene construction and large scale production of a novel fibrinolytic agent (YM866) in CHO cells. Thromb Haemost 65, 1193 (1991)
7. Katoh M, Suzuki Y, Miyamoto I, Watanabe T, Mori K, Arakawa H and Gushima H: Biochemical and pharmacokinetic properties of YM866, a novel fibrinolytic agent. Thromb Haemost 65, 1193 (1991)
8. Katoh M, Shimizu Y, Kawauchi Y, Ishida J, Takayama M, Yokota M, Yano E, Kawasaki T, Katsuta K, Yano S, Morinaga T, Tsuji T, Kinoshita A, Gomi Y, Takemoto T, Itoh K, Ezoe H and Gushima H: Comparison of clearance rate of various tissue plasminogen activator (tPA) analogues. Thromb Haemost 62, 542 (1989)
9. Kawasaki T, Katoh M, Kaku S, Gushima H, Takenaka T, Yui Y and Kawai C: Thrombolytic activity of a novel modified tissue-type plasminogen activator, YM866, in a canine model of coronary thrombosis. Jpn J Pharmacol 63, 9-16 (1993)
10. Jennings RB, Sommers HM, Smyth GA, Flack HA and Linn H: Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol 70, 68-78 (1960)
11. Reimer KA, Lowe JE, Rasmussen MM and Jennings RB: The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 56, 786-794 (1977)
12. Reimer KA and Jennings RB: The "wavefront phenomenon" of myocardial ischemic cell death. II. Transmural progression of necrosis within the framework of ischemic bed size (myocardium at risk) and collateral flow. Lab Invest 40, 633-644 (1979)
13. Lavallee M, Cox D, Patrick TA and Vatner SF: Salvage of myocardial function by coronary artery reperfusion 1, 2, and 3 hours after occlusion in conscious dogs. Circ Res 53, 235-247 (1983)
14. Linderer T and Schroder R: Prehospital thrombolysis: Beneficial effects of very early treatment on infarct size and left ventricular function. J Am Coll Cardiol 22, 1304-1310 (1993)
15. National Heart Foundation of Australia Coronary Thrombolysis Group: Coronary thrombolysis and myocardial salvage by tissue plasminogen activator given up to 4 h after onset of myocardial infarction. Lancet 1, 203-207 (1988)
16. Van de Werf F for the Investigators of the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator: Lessons from the European cooperative recombinant tissue-type plasminogen activator (rt-PA) versus placebo trial. J Am Coll Cardiol 12, 14A-19A (1988)
17. Wilcox RG, Von der Lippe G, Olsson CG, Jensen G, Skene AM and Hampton JR: Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian study of early thrombolysis (ASSET). Lancet 2, 525-530 (1988)
18. Taylor GJ, Moses HW, Koester D, Colliver JA, Katholi RE, Dave JT, Woodruff RC, Mikell FL, Becker LC, Sheehan FH, Woods WT Jr, Hamm DP, Wellons HA and Schneider JA: A difference between front-loaded streptokinase and standard-dose recombinant tissue-type plasminogen activator in preserving left ventricular function after acute myocardial infarction (the central Illinois thrombolytic therapy study). Am J Cardiol 72, 1011-1014 (1993)
19. Susawa T, Yui Y, Hattori R, Takahashi M, Aoyama T, Takatsu Y, Sakaguchi K, Yui N and Kawai C: Heparin requirement in tissue-type plasminogen activator-induced experimental coronary thrombolysis: Comparison with urokinase-induced coronary thrombolysis. Jpn Circ J 51, 431-435 (1987)
20. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, Dalen J, Dodge HT, Francis CK, Hillis D, Ludbrook P, Markis JE, Mueller H, Passamani ER, Powers ER, Rao AK, Robertson T, Ross A, Ryan TJ, Sobel BE, Willerson J, Williams DO, Zaret BL and Braunwald E: Thrombolysis in myocardial infarction (TIMI) trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Circulation 76, 142-154 (1987)
21. Fishbein MC, Meerbaum S, Rit J, Lando U, Kanmatsuse K, Mercier JC, Corday E and Ganz W: Early phase acute myocardial infarct size quantification: Validation of the triphenyl tetrazolium chloride tissue enzyme staining technique. Am Heart J 101, 593-600 (1981)
22. Kawasaki T, Katoh M, Kaku S, Gushima H, Takenaka T, Yui Y and Kawai C: Thrombolysis with intracoronary administration of YM866, a novel modified tissue-type plasminogen activator, in a canine model of coronary artery thrombosis. Jpn J Pharmacol 63, 319-325 (1993)
23. Suzuki S, Saito M, Suzuki N, Kato H, Nagaoka N, Yoshitake S, Yui Y and Kawai C: Intracoronary infusion of E6010 has more potent thrombolytic activity than tissue plasminogen activator (t-PA) in dogs: a higher plasma level of E6010 than t-PA causes potent thrombolytic activity. J Cardiovasc Pharmacol 22, 834-840 (1993)
24. Suzuki S, Saito M, Suzuki N, Kato H, Nagaoka N, Yoshitake S, Mizuo H, Yuzuriha T, Yui Y and Kawai C: Thrombolytic properties of a novel modified human tissue-type plasminogen activator (E6010): a bolus injection of E6010 has equivalent potency of lysing young and aged canine coronary thrombi. J Cardiovasc Pharmacol 17, 738-746 (1991)
25. Bush LR, Mellot MJ, Kanovsky SM, Holahan MA and Patrick DH: A model of femoral artery thrombolysis in dogs. Fibrinolysis 3, 107-114 (1989)
26. Suzuki S, Saito M, Yui Y and Kawai C: A novel modified t-PA, E-6010, induces faster recovery of ventricular function after coronary thrombolysis than native t-PA in a canine thrombosis model. Jpn Circ J 59, 205-212 (1995)
27. Topol EJ, Bates ER, Walton JA, Baumann G, Wolfe S, Maino J, Bayer L, Gorman L, Kline EM, O'Neill WW and Pitt B: Community hospital administration of intravenous tissue plasminogen activator in acute myocardial infarction: improved timing, thrombolytic efficacy and ventricular function. J Am Coll Cardiol 10, 1173-1177 (1987)
28. Loren M, Garcia Frade LJ, Torrado MC and Navarro JL: Thrombus age and tissue plasminogen activator mediated thrombolysis in rats. Thromb Res 56, 67-75 (1989)
29. Yoshitake S, Kato H, Hashimoto A, Ikeda Y, Kuwada M and Mulvihill E: Characterization of various forms of modified human tissue plasminogen activators in vitro. Thromb Haemostasis 62, 542 (1989)
30. Linderer T and Schroder R: Prehospital thrombolysis: Beneficial effects of very early treatment on infarct size and left ventricular function. J Am Coll Cardiol 22, 1304-1310 (1993)